Bosh sahifaRGLS • NASDAQ
add
Regulus Therapeutics Inc
2,76 $
Seans yopilganidan keyin:(0,72%)-0,020
2,74 $
Yopilgan:25-apr, 19:39:16 (GMT-4) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
2,80 $
Kunlik diapazon
2,66 $ - 2,85 $
Yillik diapazon
0,83 $ - 2,90 $
Bozor kapitalizatsiyasi
182,83 mln USD
Oʻrtacha hajm
1,88 mln
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | — | — |
Joriy xarajat | -19,51 mln | -59,75% |
Sof foyda | -12,79 mln | -58,68% |
Sof foyda marjasi | — | — |
Har bir ulushga tushum | -0,20 | 50,00% |
EBITDA | -13,66 mln | -66,09% |
Amaldagi soliq stavkasi | 0,00% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 75,78 mln | 218,83% |
Jami aktivlari | 84,18 mln | 173,76% |
Jami passivlari | 7,77 mln | -18,72% |
Umumiy kapital | 76,41 mln | — |
Tarqatilgan aksiyalar | 66,24 mln | — |
Narxi/balansdagi bahosi | 2,39 | — |
Aktivlardan daromad | -38,62% | — |
Kapitaldan daromad | -41,53% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -12,79 mln | -58,68% |
Operatsiyalardan naqd pul | -11,84 mln | -93,39% |
Sarmoyadan naqd pul | 24,00 mln | 386,62% |
Moliyadan naqd pul | 0,00 | 100,00% |
Naqd pulning sof oʻzgarishi | 12,16 mln | 688,33% |
Boʻsh pul | -7,24 mln | -119,86% |
Haqida
Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals. Wikipedia
Tashkil etilgan
sen 2007
Sayt
Xodimlar soni
34
